Quadrature Capital Ltd Takes $144,000 Position in Cognyte Software Ltd. (NASDAQ:CGNT)

Quadrature Capital Ltd purchased a new stake in shares of Cognyte Software Ltd. (NASDAQ:CGNT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 22,354 shares of the medical device company’s stock, valued at approximately $144,000.

Several other institutional investors have also made changes to their positions in the company. Citigroup Inc. raised its stake in shares of Cognyte Software by 3.0% in the 3rd quarter. Citigroup Inc. now owns 138,749 shares of the medical device company’s stock valued at $667,000 after acquiring an additional 3,993 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Cognyte Software in the 4th quarter valued at approximately $37,000. Hillsdale Investment Management Inc. raised its stake in shares of Cognyte Software by 32.8% in the 4th quarter. Hillsdale Investment Management Inc. now owns 28,339 shares of the medical device company’s stock valued at $182,000 after acquiring an additional 7,000 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Cognyte Software by 56.1% in the 4th quarter. Mackenzie Financial Corp now owns 21,986 shares of the medical device company’s stock valued at $141,000 after acquiring an additional 7,899 shares in the last quarter. Finally, Legacy Advisors LLC raised its stake in shares of Cognyte Software by 10.7% in the 3rd quarter. Legacy Advisors LLC now owns 114,200 shares of the medical device company’s stock valued at $549,000 after acquiring an additional 11,038 shares in the last quarter. 72.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on CGNT. Needham & Company LLC reissued a “hold” rating on shares of Cognyte Software in a research note on Tuesday, June 18th. StockNews.com raised Cognyte Software from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 21st. Wedbush lifted their price target on Cognyte Software from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, June 20th. Finally, Evercore ISI lifted their price target on Cognyte Software from $5.00 to $7.50 and gave the stock an “in-line” rating in a research report on Wednesday, April 10th.

Cognyte Software Trading Down 0.4 %

CGNT opened at $7.65 on Friday. The stock has a market cap of $543.30 million, a PE ratio of -45.00 and a beta of 1.74. Cognyte Software Ltd. has a 1 year low of $4.00 and a 1 year high of $8.70. The stock’s 50 day simple moving average is $7.49 and its 200-day simple moving average is $7.18.

Cognyte Software (NASDAQ:CGNT) last released its quarterly earnings data on Tuesday, June 18th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $82.70 million for the quarter, compared to analysts’ expectations of $82.05 million. Cognyte Software had a negative return on equity of 5.94% and a negative net margin of 3.70%. Cognyte Software’s quarterly revenue was up 12.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.25) earnings per share. Equities analysts forecast that Cognyte Software Ltd. will post -0.31 earnings per share for the current fiscal year.

Cognyte Software Profile

Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company offers network intelligence analytics, threat intelligence analytics, decision intelligence analytics, and operational intelligence analytics solutions.